Cardiol Therapeutics
-
Cardiol Therapeutics’ Cannabidiol Formulation Reduced Inflammation—Phase II Topline Data Ignites the Race to Treat Acute Myocarditis
A single‐digit p-value has rarely carried such freight. Cardiol Therapeutics Inc. (NASDAQ: CRDL | TSX: CRDL) this morning unveiled…
-
Investor.Coffee (11.03.2023): Cardiol Marks Milestone, Canadians Await Job Data and MP Materials Reports Q2 Results Outpace Rare Earth Prices
Canadian Futures Canada’s financial landscape holds its breath in anticipation of the upcoming job data release. In comparison,…
-
With an effective anti-inflammatory and anti-fibrotic agent, Cardiol Therapeutics is focused on our hearts
Trialing cannabidiol-based therapies for pericarditis and myocarditis while developing new therapies for heart failure — Cardiol is well-capitalized…
-
Cardiol Furthers Clinical Trials to Advance Disruptive Cannabidiol-Based Therapies for Heart Disease
Heart disease continues to be a leading cause of death globally. According to Cardiol Therapeutics Inc. (NASDAQ: CRDL…
-
David Elsley of Cardiol Therapeutics talks about their global Phase II clinical trials for the treatment of heart diseases
In this InvestorIntel interview, Chris Thompson talks to Cardiol Therapeutics Inc.’s (NASDAQ: CRDL | TSX: CRDL) CEO, President and…
-
Cardiol Therapeutics is concerned with affairs of the heart
One thing I really enjoy about writing for InvestorIntel is all the random learning I get from reading…
